Abstract:Breast cancer poses a serious threat to women's health globally. Current radiotherapy and chemotherapy regimens can induce drug-resistance effects in cancer tissues, such as anti-apoptosis, anti-pyroptosis, and anti-necroptosis, leading to poor clinical outcomes in the treatment of breast cancer. Ferroptosis is a novel programmed cell death modality characterized by iron overload, excessive generation of reactive oxygen species, and membrane lipid peroxidation. The occurrence of ferroptosis results from the imbalance between intracellular peroxidation mechanisms (executive system) and antioxidant mechanisms (defensive system), specifically involving iron metabolism pathways, amino acid metabolism pathways, and lipid metabolism pathways. In recent years, it has been found that ferroptosis is associated with the progression of various diseases, including tumors, hypertension, diabetes, and Alzheimer's disease. Studies have confirmed that triggering ferroptosis in breast cancer cells can significantly inhibit cancer cell proliferation and invasion, and improve cancer cell sensitivity to radiotherapy and chemotherapy, making induction of ferroptosis a potential strategy for the treatment of breast cancer. This paper reviews the development of the concept of ferroptosis, the mechanisms of ferroptosis (including signaling pathways such as GSH-GPX4, FSP1-CoQ1, DHODH-CoQ10, and GCH1-BH4) in breast cancer disease, the latest research progress, and summarizes the research on ferroptosis in breast cancer disease within the framework of metabolism, reactive oxygen biology, and iron biology. The key regulatory factors and mechanisms of ferroptosis in breast cancer disease, as well as important concepts and significant open questions in the field of ferroptosis and related natural compounds, are introduced. It is hoped that future research will make further breakthroughs in the regulatory mechanisms of ferroptosis and the use of ferroptosis in treating breast cancer cells. Meanwhile, natural compounds may also become a new direction for potential drug development targeting ferroptosis in breast cancer treatment. This provides a theoretical basis and opens up a new pathway for research and the development of drugs for the prevention and treatment of breast cancer.

Metformin may induce ferroptosis by inhibiting autophagy via lncRNA H19 in breast cancer

Metformin Induces Ferroptosis byInhibiting UFMylation of SLC7A11 in Breast Cancer

Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer

Targeting Ferroptosis in Breast Cancer

Metformin induces ferroptosis through the Nrf2/HO-1 signaling in lung cancer

Metformin promotes ferroptosis and sensitivity to sorafenib in hepatocellular carcinoma cells via ATF4/STAT3

Iron Metabolism, Ferroptosis, and Lncrna in Cancer: Knowns and Unknowns

Metformin suppresses metabolic dysfunction-associated fatty liver disease by ferroptosis and apoptosis via activation of oxidative stress

Metabolism-regulated ferroptosis in cancer progression and therapy

Metformin improves nonalcoholic fatty liver disease in db/db mice by inhibiting ferroptosis

Ferritinophagy induced ferroptosis in the management of cancer

Ferroptotic Neutrophils Induce Immunosuppression and Chemoresistance in Breast Cancer

Ferroptosis in cancer therapy: a novel approach to reversing drug resistance

Broadening horizons: the multifaceted role of ferroptosis in breast cancer

The mechanisms and therapeutic targets of ferroptosis in cancer

The role of ferroptosis in breast cancer patients: a comprehensive analysis

Pharmacotranscriptomic Analysis Reveals Novel Drugs and Gene Networks Regulating Ferroptosis in Cancer

The diversified role of mitochondria in ferroptosis in cancer

Mechanism of ferroptosis in breast cancer and research progress of natural compounds regulating ferroptosis

Metformin Induces Autophagy via the AMPK-mTOR Signaling Pathway in Human Hepatocellular Carcinoma Cells

Metformin leads to accumulation of reactive oxygen species by inhibiting the NFE2L1 expression in human hepatocellular carcinoma cells